SCHEMBL1102197

SCHEMBL1102197

NC(=O)Nc1ccc2c(c1)CCc1c-2[nH]c2c(F)c(-c3ccc(N4CCCCC4)cc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 8/20 0.48
PARP1 P09874 1/20 0.40
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
ROCK1 Q13464 1/20 0.37
ACVRL1 P37023 1/20 0.36
ACVR1 Q04771 1/20 0.36
MAPT P10636 2/20 0.36
IDO1 P14902 2/20 0.36
TDO2 P48775 2/20 0.36
IKBKB O14920 1/20 0.35
GFER P55789 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102143 0.92 MPL (0.57) MPLPARP1NPC1RAB9ATP53
SCHEMBL1102236 0.90 MPL (0.49) MPLPARP1NPC1RAB9ATP53
SCHEMBL1102210 0.84 MPL (0.46) MPLPARP1SMN1; SMN2MAPK1MAPT
SCHEMBL1102077 0.83 MPL (0.69) MPLPARP1NPC1RAB9ATP53
SCHEMBL1091483 0.82 MPL (0.63) MPLIDO1TDO2
SCHEMBL1102140 0.82 MPL (0.53) MPLPARP1IDO1TDO2
SCHEMBL1102085 0.82 MPL (0.57) MPLPARP1NPC1RAB9ATP53
SCHEMBL1090937 0.81 MPL (0.73) MPL
SCHEMBL1102080 0.81 MPL (0.48) MPL
SCHEMBL1102282 0.79 MPL (0.49) MPLNPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO MPL 1/4885PARP1 782/4885NPC1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.